$1.61
0.03[1.90%]
Last update: 8:08AM Get Real Time Here
Iterum Therapeutics
(NASDAQ:ITRM)Iterum Therapeutics Stock (NASDAQ:ITRM), Analyst Ratings, Price Targets, Predictions
Iterum Therapeutics PLC has a consensus price target of $3, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 1, 2024, March 6, 2024, and February 7, 2024. With an average price target of $6 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 272.67% upside for Iterum Therapeutics PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Gabelli & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Iterum Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/01/2024 | ITRM | Buy Now | Iterum Therapeutics | $1.61 | 272.67% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | ITRM | Buy Now | Iterum Therapeutics | $1.61 | 272.67% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | ITRM | Buy Now | Iterum Therapeutics | $1.61 | 272.67% | HC Wainwright & Co. | Ed Arce | $6 → $6 | Upgrade | Neutral → Buy | Get Alert |
| 07/27/2021 | ITRM | Buy Now | Iterum Therapeutics | $1.61 | — | Gabelli & Co. | Kevin Kedra | — | Upgrade | Sell → Hold | Get Alert |
| 07/26/2021 | ITRM | Buy Now | Iterum Therapeutics | $1.61 | — | HC Wainwright & Co. | Ed Arce | — | Downgrade | Buy → Neutral | Get Alert |
| 05/28/2021 | ITRM | Buy Now | Iterum Therapeutics | $1.61 | — | Gabelli & Co. | Kevin Kedra | — | Upgrade | Sell → Hold | Get Alert |
FAQ
What is the target price for Iterum Therapeutics (ITRM)?
The latest price target for Iterum Therapeutics (NASDAQ: ITRM) was reported by HC Wainwright & Co. on April 1, 2024. The analyst firm set a price target for $6.00 expecting ITRM to rise to within 12 months (a possible 272.67% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Iterum Therapeutics (ITRM)?
The latest analyst rating for Iterum Therapeutics (NASDAQ: ITRM) was provided by HC Wainwright & Co., and Iterum Therapeutics reiterated their buy rating.
When was the last upgrade for Iterum Therapeutics (ITRM)?
The last upgrade for Iterum Therapeutics PLC happened on February 7, 2024 when HC Wainwright & Co. raised their price target to $6. HC Wainwright & Co. previously had a neutral for Iterum Therapeutics PLC.
When was the last downgrade for Iterum Therapeutics (ITRM)?
The last downgrade for Iterum Therapeutics PLC happened on July 26, 2021 when HC Wainwright & Co. changed their price target from N/A to N/A for Iterum Therapeutics PLC.
When is the next analyst rating going to be posted or updated for Iterum Therapeutics (ITRM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iterum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iterum Therapeutics was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
Is the Analyst Rating Iterum Therapeutics (ITRM) correct?
While ratings are subjective and will change, the latest Iterum Therapeutics (ITRM) rating was a reiterated with a price target of $0.00 to $6.00. The current price Iterum Therapeutics (ITRM) is trading at is $1.61, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.